Stay updated on Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The page adds new navigation/help links (Check who can join, How to Join a Study, Find Contact Information, How to Read a Study Record, Common Questions) and standardizes the Intervention/Treatment label while updating the revision tag to v3.6.0.
    Difference
    0.5%
    Check dated 2026-06-12T16:31:30.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The page revision was updated from v3.5.4 to v3.5.5, indicating a new version of the page's documentation.
    Difference
    0.1%
    Check dated 2026-06-05T11:46:17.000Z thumbnail image
  4. Check
    42 days ago
    Change Detected
    Summary
    The page revision indicator was updated from v3.5.3 to v3.5.4, indicating a newer build of the page. No user-facing content or study data were altered.
    Difference
    0.1%
    Check dated 2026-05-15T04:17:39.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    The page shows Revision: v3.5.3, updating the prior revision tag from v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-30T19:10:40.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    Page revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-16T11:18:09.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    Updated eligibility criteria now allow concurrent hormonal or anti-HER2 therapy if brain metastases progress; MRI criteria were revised to require at least 2 untreated measurable brain metastases (≥3 mm) within two weeks before treatment, and prior subtotal resection is permitted if residual disease <4 cm.
    Difference
    0.5%
    Check dated 2026-04-02T05:42:46.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and SRS for Brain Metastases in Breast Cancer: Clinical Trial page.